Market Cap 241.48M
Revenue (ttm) 0.00
Net Income (ttm) -20.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 87,700
Avg Vol 51,096
Day's Range N/A - N/A
Shares Out 21.70M
Stochastic %K 90%
Beta N/A
Analysts Strong Sell
Price Target $31.25

Company Profile

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in the Phase 2 clinical trial for...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 225 7696
Address:
4370 La Jolla Village Drive, Suite 1050, San Diego, United States